TRIV-509 / Triveni Bio - LARVOL DELTA

TRIV-509 is the subject of an ongoing Phase 2 proof-of-concept trial with data expected end of 2026. (PRNewswire)

P2 data • Atopic Dermatitis

509-101: A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis (clinicaltrialsregister.eu) - P1/2 | N=54 | Active, not recruiting | Sponsor: Triveni Bio Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study Evaluating TRIV-509 in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=95 | Active, not recruiting | Sponsor: Triveni Bio | Recruiting ➔ Active, not recruiting

Enrollment closed • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

509-102/ CHDR2443: A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis. (clinicaltrialsregister.eu) - P1 | N=48 | Recruiting | Sponsor: Triveni Bio Inc.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

509-101: A study to investigate the efficacy and safety of TRIV-509 compared with placebo in adults with moderate to severe atopic dermatitis (clinicaltrialsregister.eu) - P1/2 | N=54 | Recruiting | Sponsor: Triveni Bio Inc.

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

KLK5 and KLK7 is overexpressed in atopic dermatitis and correlates with epidermal thickness (ISDS 2025) - "This finding may correlate with severity of disease. Clinical trials of TRIV-509, an antibody inhibitor of KLK5/7, are underway in AD."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • KLK5 • KLK7

TRIV-509, a dual inhibitor of KLK5 and KLK7, normalizes epidermal hyper-proliferation, improves barrier integrity and reduces secretion of inflammatory cytokines in atopic dermatitis skin explants (EADV 2025) - "Approved biologics such as dupilumab, lebrikizumab, and tralokinumab directly target the IL- 4/IL-13 inflammatory pathway. Inhibition of KLK5 and KLK7 ameliorates the AD epidermal phenotype in ex vivo explant cultures by normalizing epidermal keratinocyte proliferation, improving barrier integrity, and reducing secretion of AD- associated cytokines. These data support therapeutic rationale for KLK5 and KLK7 inhibition and ongoing clinical development of TRIV-509 in AD."

Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • FLG • IL13 • KLK5 • KLK7

A Study Evaluating TRIV-509 in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=90 | Recruiting | Sponsor: Triveni Bio | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study Evaluating TRIV-509 in Atopic Dermatitis (clinicaltrials.gov) - P2 | N=90 | Not yet recruiting | Sponsor: Triveni Bio

New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants (SID 2025) - "Finally, TRIV-509 significantly increased the number of DSG1+ cells in the appropriate layers of the epidermis. Together this data demonstrates that KLK5 and KLK7 inhibition rapidly improves the barrier integrity and markers of epidermal differentiation ex vivo, thereby highlighting the therapeutic potential of TRIV-509 in AD."

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • Pruritus • DSC1 • KLK5 • KLK7

Triveni Bio Doses First Healthy Volunteers in Clinical Trial for TRIV-509, Coinciding with Preclinical Data Presentations Further Validating Novel Kallikrein 5/7 Biology in Atopic Dermatitis (PRNewswire) - "Triveni Bio, Inc...announced the initiation of dosing in healthy volunteers for its first-in-human Phase 1 clinical trial of TRIV-509. This study will assess the safety and tolerability of TRIV-509 and is the first of three clinical trials the company expects to begin in 2025 as Triveni advances its anti-kallikrein mechanism into patients with moderate-to-severe atopic dermatitis (AD)."

New trial • Trial status • Atopic Dermatitis

KLK5/7 targeting antibody, TRIV-509, ameliorates barrier dysfunction, inflammation and itch in atopic dermatitis models. (SID 2024) - No abstract available

Late-breaking abstract • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • KLK5